The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation
Open accessAbstract
The innate immune signaling kinase, TBK1, couples pathogen surveillance to induction of host defense mechanisms. Pathological activation of TBK1 in cancer can overcome programmed cell death cues, enabling cells to survive oncogenic stress. The mechanistic basis of TBK1 prosurvival signaling, however, has been enigmatic. Here we show that TBK1 directly activates AKT by phosphorylation of the canonical activation loop and hydrophobic motif sites independently of PDK1 and mTORC2. Upon mitogen stimulation, triggering of the innate immune response, re-exposure to glucose, or oncogene activation, TBK1 is recruited to the exocyst, where it activates AKT. In cells lacking TBK1, insulin activates AKT normally, but AKT activation by exocyst-dependent mechanisms is impaired. Discovery and characterization of a 6-aminopyrazolopyrimidine derivative, as a selective low nanomolar TBK1 inhibitor, indicates this regulatory arm can be pharmacologically perturbed independently of canonical PI3K/PDK1 signaling. Thus, AKT is a direct TBK1 substrate that connects TBK1 to prosurvival signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 2×
“…that the exocyst plays a direct role in host defense signaling by marshaling TBK1 and STING (stimulator of interferon genes) in response to cellular detection of viral replication intermediates (Bodemann and White, 2008; Chien et al., 2006; Ishikawa and Barber, 2008; Ishikawa et al., 2009).”
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
The exocyst is a Ral effector complex
Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., & White, M. A. (2002) · Nature Cell Biology · doi:10.1038/ncb728 · Cited by 423
Self-citation
Cited by
Everts, B., Amiel, E., Huang, S. C.-C., Smith, A. M., Chang, C.-H., Lam, W. Y., Redmann, V., Freitas, T. C., Blagih, J., van der Windt, G. J. W., et al. (2014) · Nature Immunology · doi:10.1038/ni.2833 · Cited by 1,064
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
The PI3K/AKT/mTOR interactive pathway
Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015) · Molecular BioSystems · doi:10.1039/c5mb00101c · Cited by 683
TBK-1 Promotes Autophagy-Mediated Antimicrobial Defense by Controlling Autophagosome Maturation
Pilli, M., Arko-Mensah, J., Ponpuak, M., Roberts, E., Master, S., Mandell, M. A., Dupont, N., Ornatowski, W., Jiang, S., Bradfute, S. B., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.04.015 · Cited by 655
mTOR complex 2 signaling and functions
Oh, W. J., & Jacinto, E. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16586 · Cited by 562
Regulation of autophagy by the Rab GTPase network
Ao, X., Zou, L., & Wu, Y. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.187 · Cited by 411
STING pathway agonism as a cancer therapeutic
Flood, B. A., Higgs, E. F., Li, S., Luke, J. J., & Gajewski, T. F. (2019) · Immunological Reviews · doi:10.1111/imr.12765 · Cited by 334
Cui, J., Li, Y., Zhu, L., Liu, D., Songyang, Z., Wang, H. Y., & Wang, R.-F. (2012) · Nature Immunology · doi:10.1038/ni.2239 · Cited by 305
Herman, M., Ciancanelli, M., Ou, Y.-H., Lorenzo, L., Klaudel-Dreszler, M., Pauwels, E., Sancho-Shimizu, V., Pérez de Diego, R., Abhyankar, A., Israelsson, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111316 · Cited by 278
Self-citationBaldwin, A. S. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01095.x · Cited by 277
Wu, S., Zhang, Q., Zhang, F., Meng, F., Liu, S., Zhou, R., Wu, Q., Li, X., Shen, L., Huang, J., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0352-z · Cited by 275
Wu, B., & Guo, W. (2015) · Journal of Cell Science · doi:10.1242/jcs.156398 · Cited by 240
Functional Dissection of the TBK1 Molecular Network
Goncalves, A., Bürckstümmer, T., Dixit, E., Scheicher, R., Górna, M. W., Karayel, E., Sugar, C., Stukalov, A., Berg, T., Kralovics, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023971 · Cited by 136
TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis
Zhu, L., Li, Y., Xie, X., Zhou, X., Gu, M., Jie, Z., Ko, C.-J., Gao, T., Hernandez, B. E., Cheng, X., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0429-8 · Cited by 109
Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence
Kolesnichenko, M., Hong, L., Liao, R., Vogt, P. K., & Sun, P. (2012) · Cell Cycle · doi:10.4161/cc.20683 · Cited by 123
TBK1, a central kinase in innate immune sensing of nucleic acids and beyond
Zhou, R., Zhang, Q., & Xu, P. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa051 · Cited by 104
Risk factors and emerging therapies in amyotrophic lateral sclerosis
Nowicka, N., Juranek, J., Juranek, J. K., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112616 · Cited by 106
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan, N., Boyer, J. L., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1762 · Cited by 102
Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies
Hasan, M., & Yan, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.04.008 · Cited by 83
Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice
Brenner, D., Sieverding, K., Bruno, C., Lüningschrör, P., Buck, E., Mungwa, S., Fischer, L., Brockmann, S. J., Ulmer, J., Bliederhäuser, C., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180729 · Cited by 83
Torra, A., Parent, A., Cuadros, T., Rodríguez-Galván, B., Ruiz-Bronchal, E., Ballabio, A., Bortolozzi, A., Vila, M., & Bové, J. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.022 · Cited by 88
TANK-binding kinase 1 as a novel therapeutic target for viral diseases
Zhao, C., & Zhao, W. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1601702 · Cited by 61
Lee, M. S. J., Inoue, T., Ise, W., Matsuo-Dapaah, J., Wing, J. B., Temizoz, B., Kobiyama, K., Hayashi, T., Patil, A., Sakaguchi, S., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211336 · Cited by 21
Kim, J.-Y., Beg, A. A., & Haura, E. B. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.833188 · Cited by 17
Metadata
- Authors
- Ou, Y.-H., Torres, M., Ram, R., Formstecher, E., Roland, C., Cheng, T., Brekken, R., Wurz, R., Tasker, A., Polverino, T., Tan, S.-L., & White, M. A.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 41
- Issue
- 4
- Pages
- 458-470
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2025732964
- Cited by
- 226
- References
- 6
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.